The present invention relates to a pharmaceutical active compound or its salt of the formula to: Formula 1 Wherein, XY is -N (R 2 ) - CH (R 3 ) -, -CH (R 3 ) - N (R 2 ) -, -NH-NH-, -O-CHR 3 -, -CHR 3 -O-, -S-CHR 3 -, -CHR 3 -S- or -CHR 3 -CHR 3 - and R 1 is hydrogen, halogen, lower alkyl, optionally substituted by lower alkoxy, lower alkoxy, - (CH 2 ) o - phenyl, lower alkoxy optionally substituted by - (CH 2 ) o -C (O) - phenyl, optionally substituted by lower alkoxy - (CH 2 ) o -O- phenyl, - (CH 2 ) o -O- phenyl, CF 3 , cycloalkyl, NO 2 , amino or hydroxy R 2 is hydrogen, lower alkyl, optionally substituted by hydroxy, phenyl, or benzyl R 3 and R 3 are each independently hydrogen, lower alkyl or benzyl Ar is phenyl, naphthyl, benzofuran-yl or benzo [1,3] dioxin solril gt n is 1, 2, 3 or 4 o is 0, 1, 2 or 3. The compound of formula (1) Trace amine-coupled receptors (TAAR), in particular it has been found a good affinity for gateum TAAR1. The compounds are depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinsons disease, neurodegenerative diseases such as Alzheimers disease, epilepsy , migraine, hypertension, substance abuse, or metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption or a moving image, or more disorders or function of the body temperature homeostasis, disorders of sleep or circadian rhythm, or can be used in the treatment of cardiovascular disease.본 발명은 하기 화학식 1의 화합물 또는 이의 약학적인 활성 염에 관한 것이다:화학식 1상기 식에서,X-Y는 -N(R2)-CH(R3)-, -CH(R3)-N(R2)-, -NH-NH-, -O-CHR3-, -CHR3-O-, -S-CHR3-, -CHR3-S- 또는 -CHR3-CHR3-이고R1은 수소, 할로겐, 저급 알킬, 저급 알콕시, 저급 알콕시로 선택적으로 치환된 -(CH2)o-페닐, 저급 알콕시로 선택적으로 치환된 -(CH2)o-C(O)-페닐, 저급 알콕시로 선택적으로 치환된 -(CH2)o-O-페닐, -(CH2)o-O-페닐, CF3, 사이클로알킬, NO2, 아미노 또는 하이드록시이고R2는 수소, 저급 알
